After epilepsy setback, Ovid charges confidently ahead in CNS

After epilepsy setback, Ovid charges confidently ahead in CNS

Source: 
Pharma Voice
snippet: 

Setbacks can lurk around any corner in neuroscience R&D — even when the path ahead looks clear. Ovid Therapeutics recently encountered a harsh reminder of that fact.